CilgavimabMeSH Supplementary Concept

https://ansm.sante.fr/tableau-acces-derogatoire/tixagevimab-150-mg-cilgavimab-150-mg-solution-injectable-evusheld
2023
false
false
false
France
French
summary of product characteristics
package leaflet
cilgavimab and tixagevimab drug combination
Evusheld
drug combinations
cilgavimab
tixagevimab and cilgavimab
tixagevimab
COVID-19
COVID-19
adult
adolescent
Post-Exposure prophylaxis
risk factors
guidelines for drug use
immunologic deficiency syndromes
injections, intramuscular
SARS Coronavirus 2 B.1.1.529
SARS-CoV-2 variants

---
https://www.has-sante.fr/jcms/p_3352197/fr/evusheld-tixagevimab/cilgavimab-covid-19
2022
false
false
false
France
cilgavimab
tixagevimab
treatment outcome
insurance, health, reimbursement
drug combinations
antiviral agents
Pre-Exposure Prophylaxis
adult
adolescent
immunocompromised host
injections, intramuscular
tixagevimab and cilgavimab
evaluation of the transparency committee
Evusheld
COVID-19
cilgavimab and tixagevimab drug combination

---
https://recalls-rappels.canada.ca/fr/avis-rappel/evusheld-tixagevimab-et-cilgavimab-injectables-risque-echec-prophylaxie-ou-du
2022
false
false
false
Canada
French
English
pharmacovigilance note
canada
drug resistance, viral
cilgavimab and tixagevimab drug combination
drug combinations
tixagevimab
cilgavimab
tixagevimab and cilgavimab
antibodies, monoclonal
antiviral agents
Evusheld
injections, intramuscular
COVID-19
COVID-19
Pre-Exposure Prophylaxis
SARS-CoV-2 variants

---
https://www.has-sante.fr/jcms/p_3324748/fr/evusheld-tixagevimab/cilgavimab-150-mg-/-150-mg
2022
false
false
false
France
COVID-19
Pre-Exposure Prophylaxis
Evusheld
cilgavimab and tixagevimab drug combination
adult
adolescent
treatment outcome
insurance, health, reimbursement
drug combinations
cilgavimab
tixagevimab
antiviral agents
guidelines for drug use
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3383238/fr/evusheld-tixagevimab/cilgavimab-covid-19-adultes-et-adolescents
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, intramuscular
antiviral agents
cilgavimab
tixagevimab
drug combinations
tixagevimab and cilgavimab
package leaflet
summary of product characteristics
guidelines for drug use
evaluation of the transparency committee
adolescent
COVID-19
adult
Evusheld
cilgavimab and tixagevimab drug combination

---
https://www.has-sante.fr/jcms/p_3304034/fr/evusheld-tixagevimab/cilgavimab
https://has-sante.fr/jcms/p_3304078/fr/decision-n-2021-0312/dc/sem-du-9-decembre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-evusheld-tixagevimab/cilgavimab
https://www.has-sante.fr/jcms/p_3322640/fr/decision-n-2022-0071/dc/sem-du-3-mars-2022-du-college-de-la-haute-autorite-de-sante-modifiant-la-decision-n-2021-0312/dc/sem-du-9-decembre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-evusheld
2021
false
false
false
France
COVID-19
treatment outcome
Pre-Exposure Prophylaxis
adult
cilgavimab and tixagevimab drug combination
cilgavimab and tixagevimab drug combination
tixagevimab
cilgavimab
antiviral agents
injections
drug combinations
antibodies, neutralizing
evaluation of the transparency committee

---
https://ansm.sante.fr/actualites/evusheld-une-nouvelle-bitherapie-danticorps-monoclonaux-contre-la-covid-19-autorisee-en-acces-precoce
2021
false
false
false
France
French
drug information
COVID-19
Pre-Exposure Prophylaxis
cilgavimab and tixagevimab drug combination
tixagevimab
cilgavimab
antibodies, neutralizing
drug combinations
antibodies, monoclonal
antiviral agents
injections, intramuscular
treatment outcome
patient safety
adult
summary of product characteristics
package leaflet

---